Siegfried, a Swiss CDMO, agreed to acquire two pharmaceutical manufacturing plants from Novartis, Novartis, the Swiss multinational healthcare firm. Financial terms were not disclosed. The deal is expected to close at the end of 2020, subject to customary closing conditions. “The acquisition is perfectly in line with our corporate strategy EVOLVE and represents another major step towards our vision to create one of the most competitive integrated global networks in the CDMO industry,” Wolfgang Wienand, Siegfried CEO.